Rezolute’s (RZLT) Buy Rating Reiterated at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Rezolute (NASDAQ:RZLT) in a research report released on Monday morning,Benzinga reports.

RZLT has been the subject of a number of other reports. Craig Hallum raised Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Wedbush reaffirmed an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a report on Monday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Rezolute in a report on Wednesday, February 5th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $24.13.

Rezolute Stock Performance

Shares of Rezolute stock opened at $4.86 on Monday. Rezolute has a one year low of $1.05 and a one year high of $6.19. The company has a market cap of $281.59 million, a PE ratio of -3.83 and a beta of 1.10. The business has a 50-day simple moving average of $4.89 and a 200-day simple moving average of $4.90.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. On average, sell-side analysts predict that Rezolute will post -0.99 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Daron Evans acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the acquisition, the chief financial officer now owns 150,900 shares of the company’s stock, valued at $647,361. The trade was a 7.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 18.39% of the company’s stock.

Institutional Investors Weigh In On Rezolute

Several large investors have recently modified their holdings of RZLT. JPMorgan Chase & Co. purchased a new stake in shares of Rezolute during the third quarter worth approximately $42,000. MML Investors Services LLC purchased a new stake in shares of Rezolute during the third quarter worth approximately $57,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Rezolute during the third quarter worth approximately $65,000. Charles Schwab Investment Management Inc. raised its stake in shares of Rezolute by 65.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock worth $112,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Virtu Financial LLC raised its stake in shares of Rezolute by 58.0% during the third quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock worth $126,000 after purchasing an additional 9,551 shares during the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.